B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Open accessAbstract
BACKGROUND: PD-1 inhibitors are approved for multiple malignancies and function by stimulating T cells. However, the role of B cells in the anti-tumor activity of these drugs is unknown, as is their activity in patients who have received B cell depleting drugs or with immunoglobulin deficiencies. METHODS: We studied B cell content in 40 melanomas from patients treated with pembrolizumab or nivolumab and assessed the association with response to therapy. Murine MC38 colon cancer and YUMMER1.7 melanoma models were used to determine whether concomitant anti-CD20 antibody injections diminish the anti-tumor effects of anti-PD-1. Results were validated in muMT mice, which lack B cells. RESULTS: B cells were sparse in most melanomas and B cell content was not associated with response to anti-PD-1 or overall survival. Employing MC38 and YUMMER1.7 models, we demonstrated that anti-CD20 antibodies reduce tumor-infiltrating B cells yet had no effect on tumor growth, response to PD-1 inhibition, or survival. In muMT mice, T-cell dependent tumor rejection and anti-PD-1 responses were no different than in wildtype C57BL/6 J mice. CONCLUSIONS: The degree of tumor infiltrating B cell content is not associated with response to anti-PD-1 inhibitors in melanoma. PD-1 inhibitors cause tumor shrinkage in murine cancer models even when B cells are absent or are depleted. PD-1 inhibitors are likely to be active in patients with impaired B cell function, such as patients undergoing B cell depletion with drugs including rituximab for conditions such as B cell malignancies or autoimmune disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A recent report showed that B-cell depletion or absence had no effect on tumor growth, response to PD-1 inhibition, or survival.
“Reassuringly, a recent report showed that B-cell depletion or absence had no effect on tumor growth, response to PD-1 inhibition, or survival.89”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · see citing works
Kitamura, D., Roes, J., Kühn, R., & Rajewsky, K. (1991) · Nature · doi:10.1038/350423a0 · Cited by 1,783 · see citing works
T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
McKinney, E. F., Lee, J. C., Jayne, D. R. W., Lyons, P. A., & Smith, K. G. C. (2015) · Nature · doi:10.1038/nature14468 · Cited by 685 · see citing works
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642 · see citing works
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611 · see citing works
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Schildberg, F. A., Klein, S. R., Freeman, G. J., & Sharpe, A. H. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.002 · Cited by 537 · see citing works
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Das, R., Bar, N., Ferreira, M., Newman, A. M., Zhang, L., Bailur, J. K., Bacchiocchi, A., Kluger, H., Wei, W., Halaban, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96798 · Cited by 423 · see citing works
Self-citationXiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352 · see citing works
Yuan, J. D., Adamow, M. J., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 329 · see citing works
B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas
Affara, N. I., Ruffell, B., Medler, T. R., Gunderson, A. J., Johansson, M., Bornstein, S., Bergsland, E. K., Steinhoff, M. S., Li, Y., Gong, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.026 · Cited by 305 · see citing works
Zinzani, P. L., Ribrag, V., Moskowitz, C. H., Michot, J., Kuruvilla, J. G., Balakumaran, A., Zhang, Y., Chlosta, S., Shipp, M. A., & Armand, P. A. (2017) · Blood · doi:10.1182/blood-2016-12-758383 · Cited by 289 · see citing works
Siegel, J., Totonchy, M. B., Damsky, W., Berk-Krauss, J., Castiglione, F. M., Sznol, M., Petrylak, D. P., Fischbach, N. A., Goldberg, S. B., Decker, R. H., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.008 · Cited by 209 · see citing works
Self-citationOsta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 207 · see citing works
Wang, J., Perry, C. J., Meeth, K., Thakral, D., Damsky, W., Micevic, G., Kaech, S., Blenman, K., & Bosenberg, M. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12591 · Cited by 199 · see citing works
Self-citationDalakas, M. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418799864 · Cited by 176 · see citing works
Tumor-associated B-cells induce tumor heterogeneity and therapy resistance
Somasundaram, R., Zhang, G., Fukunaga-Kalabis, M., Perego, M., Krepler, C., Xu, X., Wagner, C., Hristova, D., Zhang, J., Tian, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00452-4 · Cited by 151 · see citing works
Marco, H., Smith, R., Jones, R. B., Guerry, M., Catapano, F., Burns, S., Chaudhry, A., Smith, K. G. C., & Jayne, D. R. W. (2014) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-15-178 · Cited by 148 · see citing works
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Zippelius, A., Schreiner, J., Herzig, P., & Müller, P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0226 · Cited by 144 · see citing works
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 134 · see citing works
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
Kao, J. C., Brickshawana, A., & Liewluck, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0878-7 · Cited by 126 · see citing works
Bekar, K. W., Owen, T., Dunn, R., Ichikawa, T., Wang, W., Wang, R., Barnard, J., Brady, S. P., Nevarez, S., Goldman, B., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27515 · Cited by 100 · see citing works
Qian, J., Zheng, Y., Zheng, C., Wang, L., Qin, H., Hong, S., Li, H., Lu, Y., He, J., Yang, J., et al. (2011) · Blood · doi:10.1182/blood-2011-07-368472 · Cited by 67 · see citing works
Ghosh, S., Hoselton, S. A., & Schuh, J. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200138 · Cited by 58 · see citing works
Murine Colon Adenocarcinomas: Methods for Selective Culture In Vitro 2
Tan, M., Holyoke, E. D., & Goldrosen, M. H. (1976) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/56.4.871 · Cited by 35 · see citing works
Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors
Venetsanaki, V., Boutis, A. L., Chrisoulidou, A., & Papakotoulas, P. (2019) · Current Oncology · doi:10.3747/co.26.4151 · Cited by 35 · see citing works
Ahmed, K. A., Wang, L., Munegowda, M. A., Mulligan, S. J., Gordon, J., Griebel, P. J., & Xiang, J. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.1211631 · Cited by 34 · see citing works
Jilaveanu, L. B., Puligandla, M., Weiss, S. A., Wang, V., Zito, C. R., Flaherty, K. T., Boeke, M., Neumeister, V. M., Camp, R. L., Adeniran, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1555 · Cited by 34 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001 · see citing works
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès‐Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 604 · see citing works
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 303 · see citing works
Laumont, C. M., & Nelson, B. H. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.017 · Cited by 255 · see citing works
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works
Meffre, E., & O’Connor, K. C. (2019) · Immunological Reviews · doi:10.1111/imr.12821 · Cited by 170 · see citing works
Self-citationHaanen, J. B. A. G., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I. J., Grivas, P. D., Larkin, J., Peters, S., Thompson, J. A., & Obéid, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000604 · Cited by 169 · see citing works
Leucine-tRNA-synthetase-2-expressing B cells contribute to colorectal cancer immunoevasion
Wang, Z., Zhou, L., Lin, S., Xia, J., Zhong, Z., Xie, Z., Xing, Y., Qie, J., Jiao, M., Li, Y., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.017 · Cited by 120 · see citing works
Kim, S. S., Sumner, W. A., Miyauchi, S., Cohen, E. E. W., Califano, J. A., & Sharabi, A. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0697 · Cited by 87 · see citing works
Anagnostou, V., Bruhm, D. C., Niknafs, N., White, J. R., Shao, X. M., Sidhom, J.-W., Stein, J. E., Tsai, H., Wang, H., Belcaid, Z., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100139 · Cited by 83 · see citing works
The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
Patel, A. J., Richter, A. G., Drayson, M. T., & Middleton, G. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02461-2 · Cited by 71 · see citing works
Adverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 77 · see citing works
Self-citationCamelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 61 · see citing works
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67 · see citing works
Checkpoint inhibitor-related renal vasculitis and use of rituximab
Mamlouk, O., Lin, J. S., Abdelrahim, M., Tchakarov, A. S., Glass, W. F., Selamet, U., Buni, M., Abdel‐Wahab, N., & Abudayyeh, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000750 · Cited by 52 · see citing works
Bruera, S., & Suarez-Almazor, M. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.928390 · Cited by 49 · see citing works
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 51 · see citing works
Intratumoral immunotherapy relies on B and T cell collaboration
Sagiv-Barfi, I., Czerwinski, D. K., Shree, T., Lohmeyer, J. J. K., & Levy, R. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn5859 · Cited by 44 · see citing works
Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity
Qin, Y., Lu, F., Lyu, K., Chang, A. E., & Li, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.881427 · Cited by 37 · see citing works
Wang, X., Zha, H., Wu, W., Yuan, T., Xie, S., Jin, Z., Long, H., Yang, F., Wang, Z., Zhang, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5029 · Cited by 34 · see citing works
Shalata, W., Weissmann, S., Gabay, S. I., Sheva, K., Saleh, O. A., Jama, A. A., Yakobson, A., & Rouvinov, K. (2022) · Cancers · doi:10.3390/cancers14215451 · Cited by 33 · see citing works
Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
Nikolaou, V. A., Tsimpidakis, A., & Stratigos, A. (2023) · Cancers · doi:10.3390/cancers15072084 · Cited by 29 · see citing works
Charabi, S., Engell-Noerregaard, L., Nilsson, A. C., & Stenør, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.655283 · Cited by 27 · see citing works
Immune signatures of checkpoint inhibitor-induced autoimmunity—A focus on neurotoxicity
Müller‐Jensen, L., Schulz, A. R., Mei, H. E., Mohr, R. U., Ulrich, C., Knape, P., Frost, N., Frischbutter, S., Kunkel, D., Schinke, C., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad198 · Cited by 26 · see citing works
Kubo, T., Hirohashi, Y., Tsukahara, T., Kanaseki, T., Murata, K., Morita, R., & Torigoe, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1976942 · Cited by 25 · see citing works
Role of B cells in immune‐related adverse events following checkpoint blockade
Dhodapkar, K. M., Duffy, A. M., & Dhodapkar, M. V. (2023) · Immunological Reviews · doi:10.1111/imr.13238 · Cited by 25 · see citing works
PD ‐1: A critical player and target for immune normalization
Liu, X., Zhao, A., Xiao, S., Li, H., Li, M., Guo, W., & Han, Q. (2024) · Immunology · doi:10.1111/imm.13755 · Cited by 26 · see citing works
Chun, J., Park, S., Lee, M., Ha, I. J., & Jeong, M.-K. (2023) · Cancers · doi:10.3390/cancers15030653 · Cited by 23 · see citing works
Characterization of immune cell populations in syngeneic murine tumor models
Snipstad, S., Bremnes, F., Haugum, M. D., & Sulheim, E. (2023) · Cancer Medicine · doi:10.1002/cam4.5784 · Cited by 25 · see citing works
Chen, C., Ma, J., Pi, C., Huang, W., Zhang, T., Fu, C., Liu, W., & Yang, Y. (2023) · Cell Discovery · doi:10.1038/s41421-023-00568-6 · Cited by 22 · see citing works
B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade
Singh, S., Roszik, J., Saini, N., Singh, V. K., Bavisi, K., Wang, Z., Vien, L., Yang, Z., Kundu, S., Davis, R. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.794684 · Cited by 22 · see citing works
The Role of B Cells in Head and Neck Cancer
Gavrielatou, N., Vathiotis, I. A., Economopoulou, P., & Psyrri, A. K. (2021) · Cancers · doi:10.3390/cancers13215383 · Cited by 21 · see citing works
Boll, L. M., Perera‐Bel, J., Rodríguez‐Vida, A., Arpí, O., Rovira, A., Juanpere-Rodero, N., de Oca, S. V. M., Hernández‐Llodrà, S., Lloreta, J., Albà, M. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42495-2 · Cited by 20 · see citing works
Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response
Che, Y., Lee, J., Abou-Taleb, F., Rieger, K. E., Satpathy, A. T., Chang, A. L. S., & Chang, H. Y. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501269122 · Cited by 16 · see citing works
Targeting phagocytosis to enhance antitumor immunity
Huntoon, K. M., Lee, D., Dong, S., Antony, A., Kim, B. Y. S., & Jiang, W. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.006 · Cited by 16 · see citing works
Deftereos, S., & Georgonikou, D. D. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.001 · Cited by 16 · see citing works
Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer
Ding, P., Wen, L., Tong, F., Zhang, R., Huang, Y., & Dong, X. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.104 · Cited by 15 · see citing works
Autoimmune complications of cancer immunotherapy
Dhodapkar, K. M. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.08.004 · Cited by 15 · see citing works
Guo, J., Hsu, C., Huang, Y., Lin, C., Huang, T., Wu, I., Lin, C., Lien, M., Kuo, H., Cheng, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.879398 · Cited by 13 · see citing works
Miao, K., & Zhang, L. (2023) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2023.08.002 · Cited by 13 · see citing works
Jessel, S., Austin, M., & Kluger, H. M. (2021) · PubMed · Cited by 11 · see citing works
Self-citationWulfken, L. M., Becker, J. C., Hayajneh, R., Wagner, A. D., Schaper‐Gerhardt, K., Flatt, N., Grimmelmann, I., & Gutzmer, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733961 · Cited by 10 · see citing works
Divergent Resistance Mechanisms to Immunotherapy Explain Responses in Different Skin Cancers
Dollinger, E., Bergman, D. R., Zhou, P., Atwood, S. X., & Nie, Q. H. (2020) · Cancers · doi:10.3390/cancers12102946 · Cited by 10 · see citing works
Gu, S. L., Nath, S. S., & Markova, A. (2023) · Pharmaceuticals · doi:10.3390/ph16111610 · Cited by 9 · see citing works
Lo, J., Heberton, M. M., Pacha, O., Huen, A., & Patel, A. B. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06548-4 · Cited by 9 · see citing works
Organoid: a promising solution to current challenges in cancer immunotherapy
Kang, X., Cheemalamarri, S. K., & Yin, Q. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00051-9 · Cited by 9 · see citing works
de Filette, J. M. K., André, S., Mey, L. D., Aspeslagh, S., Karmali, R., der Auwera, B. J. R. V., & Bravenboer, B. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01190-5 · Cited by 9 · see citing works
Qureshi, S., Arani, N., Parvathareddy, V. P., Tchakarov, A. S., Abdelrahim, M., Suarez-Almazor, M. E., Zhang, J., Gibbons, D. L., Heymach, J. V., Altan, M., et al. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1168614 · Cited by 7 · see citing works
B cell extracellular vesicles influence melanoma response to immune checkpoint therapy
Hrout, A. A., Balayev, A., Cervantes-Gracia, K., Gkelis, K., Benke-Bruderer, S., Gómez, J. M. M., Siliņa, K., Levesque, M. P., & Chahwan, R. (2025) · Science Advances · doi:10.1126/sciadv.adt4551 · Cited by 6 · see citing works
Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment
Gao, Y., Peng, Y., Chen, Y., Zeng, S., Shen, H., Martin, A., Cai, C., & Han, Y. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014745 · Cited by 6 · see citing works
Lin, Z., Xiao, S., Qi, Y., Guo, J., & Lu, L. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05803-5 · Cited by 6 · see citing works
Multiple sclerosis and cancer: Navigating a dual diagnosis
Nesbitt, C., van der Walt, A., Butzkueven, H., Devitt, B. A., & Jokubaitis, V. (2024) · Multiple Sclerosis Journal · doi:10.1177/13524585241274523 · Cited by 6 · see citing works
Bekkat, F., Seradj, M., Lengagne, R., FIORE, F., Kato, M., Lucas, B., Castellano, F., Molinier‐Frenkel, V., Richard, Y., & Prévost‐Blondel, A. (2024) · European Journal of Immunology · doi:10.1002/eji.202350615 · Cited by 6 · see citing works
An update on the safety of nivolumab for the treatment of advanced melanoma
Czarnecka, A. M., & Rutkowski, P. L. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1757068 · Cited by 6 · see citing works
Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
Saito, R., Sawada, Y., & Nakamura, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041957 · Cited by 6 · see citing works
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
Yuan, S., Hu, X., Zhao, Y., & Wang, Z. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563622 · Cited by 5 · see citing works
Rituximab for severe immune checkpoint inhibitor-related adverse events: a multicenter case series
Hermabessière, S., Jauzelon, B., Marmain, S., Wauthier, A., Viel, P. W. D., Castille, E., Padern, G., Lamoureux, A., Thomas, Q. D., Quantin, X., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04325-y · Cited by 4 · see citing works
Neuzil, K. E., Gessner, K. H., Hedgepeth, J., Wobker, S. E., Wallen, E., Morgan, K. P., Bjurlin, M. A., & Rose, T. L. (2021) · Urology · doi:10.1016/j.urology.2021.12.015 · Cited by 4 · see citing works
Rituximab for the treatment of immune checkpoint inhibitor–induced glomerulonephritis
Alasadi, Y., García, J. B., Arani, N., Page, V. D., Geng, Y., Andersen, C. R., Tchakarov, A. S., Kitchlu, A., Mamlouk, O., & Abudayyeh, A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf373 · Cited by 3 · see citing works
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity
Zhou, X., Geyer, F. K., Takimoto, J., Kolmar, H., & Rabinovich, B. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1718321 · Cited by 3 · see citing works
Zhang, J., Späth, S. S., Weissman, S. M., & Katz, S. G. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_10 · Cited by 3 · see citing works
Liu, X., Liu, S., Jiang, Z., Yang, C., Yang, X., Li, J., & Liu, H. (2023) · Immunotherapy · doi:10.2217/imt-2023-0105 · Cited by 3 · see citing works
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model
Uher, O., Vanova, K. H., Petrláková, K., Labitt, R. N., Lencova, R., Frejlachova, A., Ye, J., Wang, H., Masařík, M., Ženka, J., et al. (2024) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2024.101941 · Cited by 3 · see citing works
B cells and tumor immune escape.
Li, H., Li, G., Xu, P., & Li, Z. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.210275 · Cited by 1 · see citing works
Kalapala, J., Turunen, A. M., Burton, K. A., & Principe, D. R. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10342-1 · Cited by 1 · see citing works
Rewiring oncogenic signalling to precision ablation of metastatic cancer
Zou, X., Palafox, E., Zhao, C., Beier, K. T., Kang, C. Y., & Lin, M. Z. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01704-9 · Cited by 1 · see citing works
Rituximab as Rescue Therapy for Atezolizumab-Induced IgA Vasculitis
Ortiz, C. R., Arriola‐Montenegro, J., Sethi, S. M., & Herrmann, S. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101481 · Cited by 1 · see citing works
Case-based discussions in onco-nephrology
Henriksen, K., Hogan, J. J., Abudayyeh, A., Mistry, N. S., Koyner, J. L., & Jhaveri, K. D. (2020) · Journal of Onco-Nephrology · doi:10.1177/2399369320925485 · Cited by 1 · see citing works
Mamlouk, O., Lin, J. S., & Abudayyeh, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_9 · Cited by 1 · see citing works
Bridges, K., Pizzurro, G. A., Baysoy, A., Baskaran, J. P., Xu, Z. Z., Mathew, V., Tripple, V., LaPorte, M., Park, K., Damsky, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.28.620093 · Cited by 1 · see citing works
Self-citationPopović, A., Petković, I., Rančić, A., Dimitrijević, A., Brzački, V., Stankov, S. D., Jović, A., & Stojanovic, S. K. (2022) · AFMN Biomedicine · doi:10.5937/afmnai40-40566
Pouliasi, F., Salamaliki, C., Kanaloupitis, S., Verigou, E., Liolis, E., Koutras, A. K., Makatsoris, T., Kalofonos, C. P., Liossis, S. C., & Solomou, E. E. (2024) · Applied Sciences · doi:10.3390/app14124990
Cgas deficiency promotes tumor growth by supporting B cell persistence and angiogenesisPreprint
Chantawichitwong, P., Kumpunya, S., Wongtangprasert, T., Visitchanakun, P., Pisitkun, T., & Pisitkun, P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.24.614699
Benyahia, R., Roques, O., Ysebaert, L., Bergé, Y., Mazières, J., Syrykh, C., Colombat, M., & Bellière, J. (2025) · Journal of Nephrology · doi:10.1007/s40620-025-02246-0
Membranous Nephropathy Post Immune Checkpoint Inhibitors
Abudayyeh, A., Diab, A. K., & Tchakarov, A. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_39
Qiu, S., Zong, Z., & He, K. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2529152
Cgas deficiency promotes tumor growth by supporting B cell persistence and angiogenesis
Chantawichitwong, P., Kumpunya, S., Wongtangprasert, T., Visitchanakun, P., Pisitkun, T., & Pisitkun, P. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.105036
IgM promotes antitumor immunity to a Tn-expressing solid tumor
Nzuki, H. L., Jennings‐Gee, J. E., Trivette, M., Mosher, T. H., Adams-Sims, A. E., Hegarty, A. A., & Haas, K. M. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015127
- Authors
- Damsky, W., Jilaveanu, L., Turner, N., Perry, C., Zito, C., Tomayko, M., Leventhal, J., Herold, K., Meffre, E., Bosenberg, M., & Kluger, H. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Bosenberg, Marcus
- Kluger, Harriet M.
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-06-14
- Volume
- 7
- Issue
- 1
- Pages
- 153-153
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC6567557
- OpenAlex
- W2952471974
- Cited by
- 78
- References
- 28
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 9 · 2023: 14 · 2022: 13 · 2021: 11 · 2020: 13 · 2019: 3
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (R01 CA158167, R01 CA227473, P50 CA121974, R01 CA196660, CA204002)
- Foundation for the National Institutes of Health (K24 CA172123)
- Dermatology Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1 inhibitors, B cells, B-cell depletion, anti-CD20 monoclonal antibody, melanoma, pembrolizumab, nivolumab, tumor-infiltrating B cells, antitumor immunity, muMT mice, rituximab, antibody deficiency, colon cancer
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Aged, Animals, B-Lymphocytes, Colonic Neoplasms, Female, Humans, Male, Melanoma, Melanoma, Experimental, Skin Neoplasms, Cell Line, Tumor, Mice, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
